Trial · NCT06118047
Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
NCT06118047, Phase 2, Unknown, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Crisaborole Ointment for Skin Toxicity Induced by Cetuximab. Trials, record NCT06118047. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06118047
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
- NCT number
- NCT06118047
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 33 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- Metastatic Colorectal Cancer, Cetuximab, Skin Toxicity
- Interventions
- Crisaborole Ointment, Cetuximab
- First posted
- 2023-11-07
- Last updated
- 2023-11-07
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Remission rate of EGFR inhibitor-related acneiform eruption | From date of randomization until the date of remission，assessed up to 8 weeks. | Grading of acneiform eruption would be assessed according to National Cancer Institute (NCI) Common Terminology Criteria Adverse Events (CTCAE) 5.0. Remission was defined as a reduction in acneiform eruption from grade 2 to grade 1 or grade 3 to grade 2 sustained for at least 2 weeks. |
| Secondary | Remission time of EGFR inhibitor-related acneiform eruption | From date of randomization until the date of remission，assessed up to 8 weeks. | Grading of acneiform eruption would be assessed according to NCI-CTCAE 5.0. Remission was defined as a reduction in acneiform eruption from grade 2 to grade 1 or grade 3 to grade 2 sustained for at least 2 weeks |
| Secondary | Cetuximab treatment discontinuation rate | 8 weeks from randomization. | Rate of Cetuximab treatment discontinuation due to skin toxicity |
| Secondary | Cetuximab dose reduction rate | 8 weeks from randomization. | Rate of Cetuximab dose reduction due to skin toxicity |
| Secondary | Level of paronychia, xeroderma and pruritus | 8 weeks from randomization. | Grading of paronychia, xeroderma and pruritus would be assessed according to NCI-CTCAE 5.0. |
| Secondary | Quality of life (FACT-EGFRI-18) | The 0,2,4,6,8,10,12 weeks from randomization. | Functional Assessment of Cancer Therapy （FACT）questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors （FACT-EGFRI-18） |
| Secondary | Quality of life（EORTC QLQ-C30) | The 0,2,4,6,8,10,12 weeks from randomization. | Questionnaire of the European Organisation for Research and Treatment of Cancer quality of life (EORTC QLQ-C30) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06118047
GET https://conductscience.org/api/trials/v1/NCT06118047/registered